The stock of Celldex Therapeutics Inc. (NASDAQ: CLDX) has decreased by -12.24 when compared to last closing price of 41.99. Despite this, the company has experienced a -5.12% fall in its stock price over the last five trading sessions. globenewswire.com reported 2024-07-29 that HAMPTON, N.J., July 29, 2024 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive topline results from the Company’s Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD). The study includes patients who remain symptomatic despite treatment with antihistamines. Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for mast cell function and survival. CIndU is characterized by the occurrence of hives or wheals that have an attributable trigger associated with them—exposure to cold temperatures in ColdU and scratching/rubbing of the skin in SD. Mast cell activation is known to be a critical driver in ColdU and SD.
Is It Worth Investing in Celldex Therapeutics Inc. (NASDAQ: CLDX) Right Now?
The 36-month beta value for CLDX is also noteworthy at 1.57. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CLDX is 64.43M, and at present, short sellers hold a 11.47% of that float. The average trading volume of CLDX on July 30, 2024 was 664.14K shares.
CLDX’s Market Performance
CLDX stock saw a decrease of -5.12% in the past week, with a monthly decline of -0.43% and a quarterly a decrease of -0.41%. The volatility ratio for the week is 8.35%, and the volatility levels for the last 30 days are 5.43% for Celldex Therapeutics Inc. (CLDX). The simple moving average for the past 20 days is -4.70% for CLDX’s stock, with a 0.73% simple moving average for the past 200 days.
Analysts’ Opinion of CLDX
Many brokerage firms have already submitted their reports for CLDX stocks, with Stifel repeating the rating for CLDX by listing it as a “Buy.” The predicted price for CLDX in the upcoming period, according to Stifel is $58 based on the research report published on June 18, 2024 of the current year 2024.
Wolfe Research, on the other hand, stated in their research note that they expect to see CLDX reach a price target of $51. The rating they have provided for CLDX stocks is “Outperform” according to the report published on June 11th, 2024.
CLDX Trading at -0.16% from the 50-Day Moving Average
After a stumble in the market that brought CLDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -30.71% of loss for the given period.
Volatility was left at 5.43%, however, over the last 30 days, the volatility rate increased by 8.35%, as shares sank -4.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.91% lower at present.
During the last 5 trading sessions, CLDX fell by -4.27%, which changed the moving average for the period of 200-days by +32.74% in comparison to the 20-day moving average, which settled at $38.58. In addition, Celldex Therapeutics Inc. saw -7.09% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CLDX starting from Crowley Elizabeth, who sale 30,000 shares at the price of $34.87 back on Jun 14 ’24. After this action, Crowley Elizabeth now owns 9,074 shares of Celldex Therapeutics Inc., valued at $1,045,962 using the latest closing price.
Martin Samuel Bates, the SVP AND CFO of Celldex Therapeutics Inc., sale 17,172 shares at $35.42 during a trade that took place back on Jun 14 ’24, which means that Martin Samuel Bates is holding 28,125 shares at $608,315 based on the most recent closing price.
Stock Fundamentals for CLDX
Current profitability levels for the company are sitting at:
- -24.73 for the present operating margin
- 0.5 for the gross margin
The net margin for Celldex Therapeutics Inc. stands at -23.86. The total capital return value is set at -0.18. Equity return is now at value -25.39, with -24.28 for asset returns.
Based on Celldex Therapeutics Inc. (CLDX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -56.46. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -48.29.
Currently, EBITDA for the company is -139.03 million with net debt to EBITDA at 0.74. When we switch over and look at the enterprise to sales, we see a ratio of 383.68. The receivables turnover for the company is 0.82for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 31.77.
Conclusion
In summary, Celldex Therapeutics Inc. (CLDX) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
